Treats hypertension. Sold as Cozaar, Arbli. Every FDA application for this active ingredient: 2 branded and 25 generic.
As of Nov 16, 2026, FDA lists 27 applications for Losartan Potassium (sold as Cozaar, Arbli), first approved Apr 14, 1995, with 4 new uses approved and 1 published complete response letter.
| Losartan Potassium | Part D | $362M | +2% | 9,517,298 |
| Cozaar | Part D | $4.2M | -3% | 2,732 |
| Arbli | Part D | $14K | New | 16 |
| Apr 14, 1995 | CozaarNDA 20386 · New molecular entity | Organon | 50 | Marketed |
| Apr 6, 2010 | Losartan PotassiumANDA 76958 | Teva | 10 | Discontinued |
| Oct 6, 2010 | Losartan PotassiumANDA 77424 | Chartwell Rx | 7 | Marketed |
| Oct 6, 2010 | Losartan PotassiumANDA 77459 | Hikma | 10 | Discontinued |
| Oct 6, 2010 | Losartan PotassiumANDA 78232 | Lupin Ltd | 12 | Marketed |
| Oct 6, 2010 | Losartan PotassiumANDA 78243 | Zydus Pharms USA Inc | 15 | Marketed |
| Oct 6, 2010 | Losartan PotassiumANDA 90083 | Aurobindo Pharma | 11 | Marketed |
| Oct 6, 2010 | Losartan PotassiumANDA 90382 | Strides Pharma | 9 | Marketed |
| Oct 6, 2010 | Losartan PotassiumANDA 90428 | Alembic Pharms Ltd | 10 | Marketed |
| Oct 6, 2010 | Losartan PotassiumANDA 90467 | Torrent Pharms | 11 | Discontinued |
| Oct 6, 2010 | Losartan PotassiumANDA 90544 | Aiping Pharm Inc | 6 | Marketed |
| Oct 6, 2010 | Losartan PotassiumANDA 90790 | Apotex Corp | 7 | Discontinued |
| Oct 6, 2010 | Losartan PotassiumANDA 91129 | Watson Labs | 5 | Marketed |
| Oct 6, 2010 | Losartan PotassiumANDA 91590 | Mylan | 4 | Discontinued |
| Jun 6, 2011 | Losartan PotassiumANDA 91497 | Prinston Inc | 6 | Marketed |
| May 30, 2012 | Losartan PotassiumANDA 202230 | Macleods Pharms Ltd | 7 | Marketed |
| Sep 18, 2012 | Losartan PotassiumANDA 201170 | Jubilant Cadista | 7 | Marketed |
| Sep 24, 2012 | Losartan PotassiumANDA 91541 | Micro Labs | 8 | Discontinued |
| Aug 30, 2013 | Losartan PotassiumANDA 200290 | Ipca Labs Ltd | 6 | Discontinued |
| Aug 12, 2015 | Losartan PotassiumANDA 203835 | Hetero Labs Ltd V | 4 | Marketed |
| Oct 14, 2015 | Losartan PotassiumANDA 203030 | Unichem | 4 | Marketed |
| Apr 4, 2019 | Losartan PotassiumANDA 204795 | Hisun Pharm Hangzhou | 0 | Discontinued |
| Feb 23, 2023 | Losartan PotassiumANDA 215959 | Granules | 1 | Marketed |
| Aug 14, 2023 | Losartan PotassiumANDA 217396 | Msn | 1 | Marketed |
| Jun 4, 2024 | Losartan PotassiumANDA 218551 | Apotex | 1 | Discontinued |
| Mar 13, 2025 | ArbliNDA 218772 · New dosage form | Scienture | 1 | Marketed |
| Sep 19, 2025 | Losartan PotassiumANDA 219859 | Graviti Pharms | 0 | Marketed |
| Letter | Product | Now |
|---|---|---|
| Aug 19, 2024 | Losartan potassiumProduct Quality | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA